Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024771 | 0.94 | MAPT (0.69) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2030793 | 0.93 | MAPT (0.67) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2031525 | 0.91 | MAPT (0.65) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2027232 | 0.91 | MAPT (0.67) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL496638 | 0.90 | MAPT (0.63) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2029914 | 0.89 | MAPT (0.62) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2828810 | 0.89 | MAPT (0.62) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2027745 | 0.89 | MAPT (0.62) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2028935 | 0.87 | MAPT (0.60) | MAPTNPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2027810 | 0.87 | MAPT (0.60) | MAPTNPC1LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | claimed |
| US-20110136803-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2011-06-09 | — | — | US | claimed |
| US-7671050-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | claimed |
| US-20080280907-A1 | Triazolophthalazines | AALTANA PHARMA AG (DE) | 2008-11-13 | — | — | US | claimed |
| EP-1874775-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | claimed |
| WO-2006072612-A2 | TRIAZOLOPHTHALAZINES AS PDE2- INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | claimed |
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280907-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | MAPT 3537/4885NPC1 3725/4885LMNA 3745/4885 |
| US-20110136803-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | MAPT 3537/4885NPC1 3725/4885LMNA 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.